Key facts
- This page summarizes Neera Clase's Form 3 filing for Tarsus Pharmaceuticals, Inc. (TARS).
- 0 reported transactions and 10 derivative rows are listed below.
- Accepted by SEC: 05 Nov 2026, 16:39.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Options granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan (the "Plan"). 25% of the option shares vested and became exercisable on August 16, 2022, and 1/48th of the option shares vested each month thereafter for a period of 3 years.
Footnote F2
Options granted under the Plan. 25% of the option shares vested and became exercisable on March 9, 2023, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
Footnote F3
Options granted under the Plan. 25% of the option shares vested and became exercisable on March 8, 2024, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
Footnote F4
Options granted under the Plan. 25% of the option shares vested and became exercisable on March 7, 2025, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
Footnote F5
Options granted under the Plan. 25% of the option shares vested and became exercisable on March 5, 2026, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
Footnote F6
Options granted under the Plan. 25% of the option shares will vest and become exercisable on March 5, 2027, and 1/48th of the option shares each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
Footnote F7
Restricted Stock Units ("RSUs") granted under the Plan. The RSUs shall vest on March 15, 2027, subject to the Reporting Person's continuous service.
Footnote F8
RSUs granted under the Plan. The RSUs shall vest in equal annual installments on March 15, 2027 and March 15, 2028, subject to the Reporting Person's continuous service.
Footnote F9
RSUs granted under the Plan. The RSUs shall vest in equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.
Footnote F10
RSUs granted under the Plan. The RSUs shall vest in equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.
SEC remarks
Exhibit 24 - Power of Attorney